标题
Molecular pathology of lung cancer: key to personalized medicine
作者
关键词
-
出版物
MODERN PATHOLOGY
Volume 25, Issue 3, Pages 347-369
出版商
Springer Nature
发表日期
2012-01-28
DOI
10.1038/modpathol.2011.215
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Non–Small Cell Lung Cancer
- (2017) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- EGFR-mutated lung cancer: a paradigm of molecular oncology
- (2015) Oncotarget
- Adenosquamous Carcinoma of the Lung
- (2011) Naobumi Tochigi et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Cancer statistics, 2011
- (2011) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
- (2011) J. Qi et al. CANCER RESEARCH
- Targeting Anaplastic Lymphoma Kinase in Lung Cancer
- (2011) A. T. Shaw et al. CLINICAL CANCER RESEARCH
- Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
- (2011) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance
- (2011) Rebekka Krumbach et al. EUROPEAN JOURNAL OF CANCER
- The landscape ofEGFRpathways and personalized management of non-small-cell lung cancer
- (2011) Liang Cheng et al. Future Oncology
- Large-Cell Neuroendocrine Carcinoma of the Lung Harboring EGFR Mutation and Responding to Gefitinib
- (2011) Tommaso M. De Pas et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma
- (2011) Yasushi Yatabe et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations
- (2011) Paul K. Paik et al. JOURNAL OF CLINICAL ONCOLOGY
- Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
- (2011) Qing Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
- (2011) Vicki Leigh Keedy et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice
- (2011) Leina Sun et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- (2011) William D. Travis et al. Journal of Thoracic Oncology
- Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
- (2011) Kenneth J O'Byrne et al. LANCET ONCOLOGY
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum–gemcitabine chemotherapy
- (2011) M. Joerger et al. LUNG CANCER
- Correction: Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
- (2011) F. Janku et al. Nature Reviews Clinical Oncology
- The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models
- (2011) E Normant et al. ONCOGENE
- Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCR
- (2011) Ronald van Eijk et al. PLoS One
- Screening for EGFR and KRAS Mutations in Endobronchial Ultrasound Derived Transbronchial Needle Aspirates in Non-Small Cell Lung Cancer Using COLD-PCR
- (2011) George Santis et al. PLoS One
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- Correlation of genes associated with drug response to prognosis of large cell lung carcinoma
- (2011) Cheng Chen et al. Chinese Journal of Cancer
- Visualization of FISH Probes by Dual-Color Chromogenic In Situ Hybridization
- (2010) Kirsten Hoff et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry
- (2010) Lynette M. Sholl et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Discovery of selective irreversible inhibitors for EGFR-T790M
- (2010) Wenjun Zhou et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor-Activating Mutations
- (2010) C. Yamamoto et al. CANCER RESEARCH
- Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency
- (2010) U. McDermott et al. CANCER RESEARCH
- MEK1/2 Inhibitors AS703026 and AZD6244 May Be Potential Therapies forKRASMutated Colorectal Cancer That Is Resistant to EGFR Monoclonal Antibody Therapy
- (2010) Juyong Yoon et al. CANCER RESEARCH
- Role of Survivin in EGFR Inhibitor-Induced Apoptosis in Non-Small Cell Lung Cancers Positive for EGFR Mutations
- (2010) K. Okamoto et al. CANCER RESEARCH
- Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy
- (2010) Hongbin Ji CANCER SCIENCE
- Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?
- (2010) David Paez et al. CANCER SCIENCE
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
- (2010) K. Suda et al. CLINICAL CANCER RESEARCH
- Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
- (2010) Geoffrey R. Oxnard et al. CLINICAL CANCER RESEARCH
- A Review of Epidermal Growth Factor Receptor/HER2 Inhibitors in the Treatment of Patients With Non–Small-Cell Lung Cancer
- (2010) Ramaswamy Govindan Clinical Lung Cancer
- Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies
- (2010) Sarah Barton et al. CURRENT CANCER DRUG TARGETS
- The biology and treatment of EML4-ALK non-small cell lung cancer
- (2010) Takaaki Sasaki et al. EUROPEAN JOURNAL OF CANCER
- A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond
- (2010) Martin Reck Expert Review of Anticancer Therapy
- Clinical implications ofMETgene copy number in lung cancer
- (2010) Luca Toschi et al. Future Oncology
- Personalized Medicine in Non–Small-Cell Lung Cancer: IsKRASa Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?
- (2010) Patrick J. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer
- (2010) Shirin Khambata-Ford et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR
- (2010) Marie Brevet et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- KRAS and BRAF: drug targets and predictive biomarkers
- (2010) Efsevia Vakiani et al. JOURNAL OF PATHOLOGY
- ALK, Lung Cancer, and Personalized Therapy: Portent of the Future?
- (2010) Ken Garber JNCI-Journal of the National Cancer Institute
- Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer
- (2010) David R. Gandara et al. Journal of Thoracic Oncology
- Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans
- (2010) J. Matthew Reinersman et al. Journal of Thoracic Oncology
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
- (2010) Roy S Herbst et al. LANCET ONCOLOGY
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- (2010) Federico Cappuzzo et al. LANCET ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Recurrent EML4–ALK-associated lung adenocarcinoma with a slow clinical course
- (2010) Shuji Murakami et al. LUNG CANCER
- EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations
- (2010) M. Tiseo et al. LUNG CANCER
- Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
- (2010) Xuchao Zhang et al. Molecular Cancer
- Cancer-Associated Fibroblasts Derived from EGFR-TKI-Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs
- (2010) S. R. Mink et al. MOLECULAR CANCER RESEARCH
- KRASmutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach
- (2010) Young-Kwang Yoon et al. MOLECULAR CARCINOGENESIS
- Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
- (2010) Mallika Singh et al. NATURE BIOTECHNOLOGY
- The molecular pathology of cancer
- (2010) Timothy J. R. Harris et al. Nature Reviews Clinical Oncology
- Understanding resistance to EGFR inhibitors—impact on future treatment strategies
- (2010) Deric L. Wheeler et al. Nature Reviews Clinical Oncology
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
- (2010) D Ercan et al. ONCOGENE
- EGFR Signaling and Drug Discovery
- (2010) Georg Lurje et al. ONCOLOGY
- The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation
- (2010) I. Vivanco et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC
- (2010) Roland Penzel et al. VIRCHOWS ARCHIV
- Micropapillary Lung Adenocarcinoma
- (2009) Rosane De Oliveira Duarte Achcar et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues
- (2009) Maria Paola Martelli et al. AMERICAN JOURNAL OF PATHOLOGY
- Anaplastic lymphoma kinase: signalling in development and disease
- (2009) Ruth H. Palmer et al. BIOCHEMICAL JOURNAL
- TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS
- (2009) Daisy Wing-Sze Wong et al. CANCER
- PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
- (2009) M. L. Sos et al. CANCER RESEARCH
- Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2009) I. J. Dahabreh et al. CLINICAL CANCER RESEARCH
- Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2009) P. S. Hammerman et al. CLINICAL CANCER RESEARCH
- KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803
- (2009) S. Ogino et al. CLINICAL CANCER RESEARCH
- Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer
- (2009) L. Horn et al. CLINICAL CANCER RESEARCH
- Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
- (2009) D. M. Jackman et al. CLINICAL CANCER RESEARCH
- EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases
- (2009) K. Schmid et al. CLINICAL CANCER RESEARCH
- Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
- (2009) J. P. Eder et al. CLINICAL CANCER RESEARCH
- KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
- (2009) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer
- (2009) J. Yu et al. CLINICAL CANCER RESEARCH
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
- (2009) S. J. Rodig et al. CLINICAL CANCER RESEARCH
- Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
- (2009) L. M. Ellis et al. CLINICAL CANCER RESEARCH
- Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- (2009) W. Wang et al. CLINICAL CANCER RESEARCH
- Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
- (2009) Kim-Son H. Nguyen et al. Clinical Lung Cancer
- Mechanisms of tumor resistance to EGFR-targeted therapies
- (2009) Elizabeth A Hopper-Borge et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
- (2009) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
- (2009) Federico Cappuzzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
- (2009) David Jackman et al. JOURNAL OF CLINICAL ONCOLOGY
- Evidence for Common Clonal Origin of Multifocal Lung Cancers
- (2009) Xiaoyan Wang et al. JNCI-Journal of the National Cancer Institute
- Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
- (2009) Salvatore Siena et al. JNCI-Journal of the National Cancer Institute
- MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort
- (2009) Michèle Beau-Faller et al. Journal of Thoracic Oncology
- Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites
- (2009) Carlos Gomez-Roca et al. Journal of Thoracic Oncology
- Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer
- (2009) Howard West et al. Journal of Thoracic Oncology
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
- (2009) Ezra EW Cohen et al. LANCET ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies
- (2009) Chen Mao et al. LUNG CANCER
- EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset
- (2009) Kentaro Inamura et al. MODERN PATHOLOGY
- Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations
- (2009) I. Y.-S. Tam et al. MOLECULAR CANCER THERAPEUTICS
- Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
- (2009) Helena Linardou et al. Nature Reviews Clinical Oncology
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
- (2009) A F Gazdar ONCOGENE
- The Histopathology of BRAF-V600E–mutated Lung Adenocarcinoma
- (2008) Samuel A. Yousem et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
- (2008) K Tamura et al. BRITISH JOURNAL OF CANCER
- Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
- (2008) C Lemos et al. BRITISH JOURNAL OF CANCER
- Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors
- (2008) U. McDermott et al. CANCER RESEARCH
- Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer
- (2008) Y. L. Choi et al. CANCER RESEARCH
- Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
- (2008) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- Prospective Study of the Accuracy of EGFR Mutational Analysis by High-Resolution Melting Analysis in Small Samples Obtained from Patients with Non-Small Cell Lung Cancer
- (2008) T. Fukui et al. CLINICAL CANCER RESEARCH
- Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
- (2008) D. B. Costa et al. CLINICAL CANCER RESEARCH
- Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response
- (2008) J.-Y. Wu et al. CLINICAL CANCER RESEARCH
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
- Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma
- (2008) Naoki Hijiya et al. HUMAN PATHOLOGY
- Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
- (2008) Amit Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- IncreasedEGFRGene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy
- (2008) Fred R. Hirsch et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting
- (2008) David A. Eberhard et al. JOURNAL OF CLINICAL ONCOLOGY
- Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy
- (2008) Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
- (2008) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR Mutations in Lung Adenocarcinomas
- (2008) Allan R. Li et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
- (2008) Kentaro Inamura et al. Journal of Thoracic Oncology
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
- (2008) Helena Linardou et al. LANCET ONCOLOGY
- Impact of EGFR mutation analysis in non-small cell lung cancer
- (2008) Hiromasa Yamamoto et al. LUNG CANCER
- Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation
- (2008) Hideki Endoh et al. LUNG CANCER
- Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma
- (2008) Xiaoyan Wang et al. MODERN PATHOLOGY
- Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
- (2008) Marc Ladanyi et al. MODERN PATHOLOGY
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lung Cancer
- (2008) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of Mutations inEGFRin Circulating Lung-Cancer Cells
- (2008) Shyamala Maheswaran et al. NEW ENGLAND JOURNAL OF MEDICINE
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: A fluorescence in situ hybridization and immunohistochemical analysis
- (2008) Rebecca A. Marks et al. PROSTATE
- ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer
- (2007) Kyung-Hun Lee et al. LUNG CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search